4.3 Article

Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders

Journal

JOURNAL OF NEUROIMMUNOLOGY
Volume 232, Issue 1-2, Pages 196-199

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2010.10.025

Keywords

Autism; Chemokines; Behavior; Immunity

Funding

  1. NIEHS Children's Center [P01 ES011269]
  2. US EPA STAR [R833292, R829388]
  3. NIEHS CHARGE study [R01ES015359]
  4. Autism Speaks Foundation
  5. Peter Emch Foundation
  6. Boler Company Foundation
  7. Botsford-Johnson Foundation

Ask authors/readers for more resources

A role for immune dysfunction has been suggested in autism spectrum disorders (ASD). Elevated levels of chemokines have been detected in the brain and CSF of individuals with ASD but, to date, no study has examined chemokine levels in the plasma of children with this disorder. In the current study, we determined whether there were differential profiles of chemokines in the plasma of children with ASD compared to age-matched typically developing controls and children with developmental disabilities other than ASD. Increased MCP-1, RANTES and eotaxin levels were observed in ASD children compared with both control groups (p < 0.03), and increased chemokine production was associated with higher aberrant behavior scores and more impaired developmental and adaptive function.. Elevated MCP-1, RANTES and eotaxin in some ASD children and their association with more impaired behaviors may have etiological significance. Chemokines and their receptors might provide unique targets for future therapies in ASD. (C) 2010 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available